<DOC>
	<DOCNO>NCT01841333</DOCNO>
	<brief_summary>This phase II trial test whether Hedgehog signal pathway inhibitor PF-04449913 decrease disease relapse high-risk patient acute leukemia donor stem cell transplant .</brief_summary>
	<brief_title>PF-04449913 For Patients With Acute Leukemia High Risk Relapse After Donor Stem Cell Transplant</brief_title>
	<detailed_description>Disease relapse common cause death allogeneic stem cell transplantation acute leukemia . Patients high risk relapse may benefit novel , biologically rational therapeutic intervention prevent outcome . PF-04449913 small molecule inhibitor hedgehog ( Hh ) pathway inhibits protein Smoothened ( SMO ) . Aberrant Hh signal may contribute survival expansion leukemia stem cell , inhibit Hh pathway eliminate cell . Therefore , target Hh may logical intervention post-transplantation set high risk relapse . The investigator propose phase 2 study PF-04449913 post-allogeneic stem cell transplantation patient high risk relapse . This open label , phase 2 study employ PF-04449913 acute leukemia patient receive allogeneic stem cell transplantation high risk relapse . Patients receive consecutive 28-day cycle PF-04449913 100 mg/day , begin post-transplantation day 80 +/- 10 day , routine post-transplant bone marrow biopsy . Treatment continue one year experience toxicity disease relapse . Seventeen patient require 80 % power detect 30 % difference one-year relapse free survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>World Health Organization ( WHO ) confirm acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , myelodysplastic syndrome ( MDS ) refractory anemia excess blast ( RAEB ) 1 2 Between day 28 50 post transplantation time initiation study drug Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Life expectancy &gt; 2 month Recipient myeloablative nonmyeloablative allogeneic hematopoietic stem cell transplant ( HSCT ) : Conditioning regimen prescribe investigator 's discretion , prospectively define myeloablative nonmyeloablative Stable engraftment , define absolute neutrophil count ( ANC ) &gt; = 1000/mm^3 platelet 25,000/mm^3 In morphologic remission ( &lt; 5 % marrow blast ) base bone marrow ( BM ) biopsy perform +/ 5 day day 28 posttransplantation day 50 posttransplantation Without clinical sign active central nervous system disease For nonmyeloablative transplant , &gt; = 50 % cluster differentiation ( CD ) 3 donor chimerism screen High risk relapse fully myeloablative HSCT , define acute leukemia : Any level minimal residual disease ( MRD ) bone marrow aspirate peripheral blood sample , routine measurement postHSCT Any patient enter HSCT MRD flow cytometry Any patient enter HSCT cytogenetic abnormality measure metaphase cytogenetics fluorescent situ hybridization ( FISH ) probe Any patient entering HSCT without morphological remission ( &gt; 5 % blast differential aspirate ) High risk relapse nonmyeloablative allogeneic HSCT acute leukemia , define : Relapse risk score &gt; 0 Any patient enter HSCT MRD flow cytometry Any patient enter HSCT cytogenetic abnormality measure metaphase cytogenetics FISH probe Any patient enter HSCT without morphological remission ( &gt; 5 % blast differential aspirate ) High risk relapse myeloablative nonmyeloablative allogeneic HSCT MDS , define : Intermediate , poor , poor cytogenetics revise International Prognostic Scoring System ( IPSS ) Aspartate aminotransferase ( AST ) , alanine aminotransferase , ( ALT ) = &lt; 3.0 x institutional upper limit normal ( ULN ) Total bilirubin = &lt; 2.0 x institutional ULN , unless document Gilbert 's syndrome Either creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) creatinine clearance &gt; 60 mL/min calculate institution 's standard formula Serum/urine pregnancy test ( female childbearing potential ) negative within 72 hour prior initiation first dose treatment ( patient childbearing potential , opinion investigator , biologically capable child sexually active ) Female patient childbearing potential sexually active male female partner childbearing potential must agree use highly effective method contraception throughout study least 90 day last dose assign treatment Subject able comply study procedure followup examination Concomitant treatment antineoplastic agent , exception , clinically indicate , prophylaxis posttransplantation set intrathecal chemotherapy tyrosine kinase inhibitor breakpoint cluster region ( BCR ) vabl Abelson murine leukemia viral oncogene homolog 1 ( Abl ) Use experimental drug therapy within 28 day baseline Inability swallow absorb drug Active uncontrolled acute fungal , bacterial , infection unresponsive therapy time study drug dose Unstable angina pectoris New York Heart Association class III IV heart failure , unless screen echocardiogram multiple gate acquisition scan perform either within 1 month prior study screen result leave ventricular ejection fraction &gt; = 45 % ( institutional low limit normal value ) Corrected QT ( QTc ) interval &gt; 470 msec Active cardiac arrhythmia rapid ventricular response ( defined heart rate great 100 beats/minute ) Known human immunodeficiency virus ( HIV ) infection Grade III/IV acute graftversushost disease ( GVHD ) Current use anticipate need food drug know strong/moderate cytochrome P450 3A4 ( CYP3A4 ) inhibitor strong CYP3A4 inducer , include administration within 7days prior study entry ; azole antifungal except Any medical , psychiatric , addictive kind disorder compromise ability subject give write informed consent and/or comply procedure Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoblastic leukemia remission</keyword>
	<keyword>Myeloid leukemia remission</keyword>
	<keyword>Recurrent lymphoblastic leukemia</keyword>
	<keyword>Recurrent myeloid leukemia</keyword>
</DOC>